Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Metadata
Title
Treatment modalities for oral verrucous carcinomas and their outcomes: contribution of radiotherapy and chemotherapy
Authors
Yasuro Yoshimura
Koichi Mishima
Seiji Obara
Yoshiki Nariai
Hitoshi Yoshimura
Takahiro Mikami
Publication date
01-08-2001
Publisher
Springer-Verlag
Published in
International Journal of Clinical Oncology / Issue 4/2001
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/PL00012104

Other articles of this Issue 4/2001

International Journal of Clinical Oncology 4/2001 Go to the issue

CANCER STATISTICS

Colorectal cancer statistics in Japan: data from JSCCR registration, 1974–1993

CASE REPORT

Allelic loss of the NF1 gene in anal malignant melanoma in a patient with neurofibromatosis type 1

OriginalPaper

Anterior approach to the second thoracic vertebral body for surgical treatment (vertebrectomy, bone grafting, and titanium alloy plate fixation)

ORIGINAL ARTICLE

Prognostic value of DNA ploidy in 653 Japanese women with node-negative breast cancer

REVIEW ARTICLE

From tumor antigens to immunotherapy

OriginalPaper

Trends in the incidence of primary intracranial tumors in Kumamoto, Japan
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits